Addex Therapeutics Files 6-K, Incorporates Press Release
Ticker: ADXN · Form: 6-K · Filed: Apr 25, 2025 · CIK: 1574232
Sentiment: neutral
Topics: filing, press-release, regulatory
TL;DR
Addex Therapeutics filed a 6-K on 4/25/25, incorporating a press release into existing SEC filings.
AI Summary
On April 25, 2025, Addex Therapeutics Ltd. announced the issuance of a press release, which is incorporated by reference into this Form 6-K filing. This press release is also being incorporated into their existing Form F-3 registration statement (Registration No. 333-255089) and Form S-8 registration statements (Registration No. 333-255124).
Why It Matters
This filing indicates ongoing corporate communications and regulatory compliance for Addex Therapeutics, potentially signaling updates relevant to investors.
Risk Assessment
Risk Level: low — This filing is primarily procedural, incorporating a previously issued press release into SEC filings without new financial or operational disclosures.
Key Numbers
- 001-39179 — Commission File Number (Identifies the specific SEC filing for Addex Therapeutics Ltd.)
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- April 25, 2025 (date) — Date of press release and filing
- 333-255089 (registration_number) — Form F-3 registration number
- 333-255124 (registration_number) — Form S-8 registration number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a press release issued by Addex Therapeutics Ltd. on April 25, 2025, and incorporate it by reference into existing SEC registration statements.
What specific registration statements are mentioned in the filing?
The filing mentions the incorporation by reference into the Form F-3 registration statement (No. 333-255089) and Form S-8 registration statements (No. 333-255124).
What is the filing date of this Form 6-K?
The filing date is April 25, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Does this filing contain new financial information?
No, this filing primarily serves to incorporate a previously issued press release and does not appear to contain new financial information itself.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 25, 2025 regarding Addex Therapeutics Ltd. (ADXN).